ArticleHerz2026
[Atrial fibrillation : An overview of the various treatment options].
Article in Herz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation is associated with a reduced quality of life, an increased risk of thromboembolic events and higher mortality. A fast and individualized treatment is essential, particularly to positively influence the progression. In addition to risk-adapted oral anticoagulation, early rhythm control is crucial for reducing the burden of symptoms as well as for decreasing hospitalization, ischemic stroke and cardiovascular death. Options for rhythm control include pharmacological strategies, electrical cardioversion, and catheter-based ablation procedures. Electrical cardioversion is particularly suitable for the acute treatment of hemodynamically unstable patients, while pharmacological treatment and catheter ablation represent long-term treatment approaches. Class IC antiarrhythmic drugs such as flecainide and propafenone are contraindicated in patients with structural heart disease.
Indexed as
Identifiers
42782286What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.